BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 34203761)

  • 1. Effects of a Novel Thiadiazole Derivative with High Anticancer Activity on Cancer Cell Immunogenic Markers: Mismatch Repair System, PD-L1 Expression, and Tumor Mutation Burden.
    Sagredou S; Dalezis P; Papadopoulou E; Voura M; Deligiorgi MV; Nikolaou M; Panayiotidis MI; Nasioulas G; Sarli V; Trafalis DT
    Pharmaceutics; 2021 Jun; 13(6):. PubMed ID: 34203761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach.
    Luchini C; Bibeau F; Ligtenberg MJL; Singh N; Nottegar A; Bosse T; Miller R; Riaz N; Douillard JY; Andre F; Scarpa A
    Ann Oncol; 2019 Aug; 30(8):1232-1243. PubMed ID: 31056702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endometrial Tumors with MSI-H and dMMR Share a Similar Tumor Immune Microenvironment.
    Song Y; Gu Y; Hu X; Wang M; He Q; Li Y
    Onco Targets Ther; 2021; 14():4485-4497. PubMed ID: 34429613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients.
    Vanderwalde A; Spetzler D; Xiao N; Gatalica Z; Marshall J
    Cancer Med; 2018 Mar; 7(3):746-756. PubMed ID: 29436178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between protein biomarkers of chemotherapy response and microsatellite status, tumor mutational burden and PD-L1 expression in cancer patients.
    Nikanjam M; Arguello D; Gatalica Z; Swensen J; Barkauskas DA; Kurzrock R
    Int J Cancer; 2020 Jun; 146(11):3087-3097. PubMed ID: 31479512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The promise of PD-1 inhibitors in gastro-esophageal cancers: microsatellite instability
    Jin Z; Yoon HH
    J Gastrointest Oncol; 2016 Oct; 7(5):771-788. PubMed ID: 27747091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mismatch repair deficiency is associated with MSI phenotype, increased tumor-infiltrating lymphocytes and PD-L1 expression in immune cells in ovarian cancer.
    Xiao X; Dong D; He W; Song L; Wang Q; Yue J; Xie L
    Gynecol Oncol; 2018 Apr; 149(1):146-154. PubMed ID: 29496294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-L1 Expression Is Significantly Associated with Tumor Mutation Burden and Microsatellite Instability Score.
    Cho YA; Lee H; Kim DG; Kim H; Ha SY; Choi YL; Jang KT; Kim KM
    Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor mutation burden, DNA mismatch repair status and checkpoint immunotherapy markers in primary and relapsed malignant rhabdoid tumors.
    Abro B; Kaushal M; Chen L; Wu R; Dehner LP; Pfeifer JD; He M
    Pathol Res Pract; 2019 Jun; 215(6):152395. PubMed ID: 31047727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Research Progress of Anti-PD-1/PD-L1 Immunotherapy Related Mechanisms and Predictive Biomarkers in NSCLC.
    Bie F; Tian H; Sun N; Zang R; Zhang M; Song P; Liu L; Peng Y; Bai G; Zhou B; Gao S
    Front Oncol; 2022; 12():769124. PubMed ID: 35223466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinct Immunological Landscapes Characterize Inherited and Sporadic Mismatch Repair Deficient Endometrial Cancer.
    Ramchander NC; Ryan NAJ; Walker TDJ; Harries L; Bolton J; Bosse T; Evans DG; Crosbie EJ
    Front Immunol; 2019; 10():3023. PubMed ID: 31998307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Programmed Death-Ligand 1 Expression, Microsatellite Instability, Epstein-Barr Virus, and Human Papillomavirus in Nasopharyngeal Carcinomas of Patients from the Philippines.
    Chang AMV; Chiosea SI; Altman A; Pagdanganan HA; Ma C
    Head Neck Pathol; 2017 Jun; 11(2):203-211. PubMed ID: 27807760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 3,6-Disubstituted 1,2,4-Triazolo[3,4-
    Sagredou S; Dalezis P; Nikoleousakos N; Nikolaou M; Voura M; Almpanakis K; Panayiotidis MI; Sarli V; Trafalis DT
    Onco Targets Ther; 2020; 13():7369-7386. PubMed ID: 32801761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A subset of patients with MSS/MSI-low-colorectal cancer showed increased CD8(+) TILs together with up-regulated IFN-γ.
    Kikuchi T; Mimura K; Okayama H; Nakayama Y; Saito K; Yamada L; Endo E; Sakamoto W; Fujita S; Endo H; Saito M; Momma T; Saze Z; Ohki S; Kono K
    Oncol Lett; 2019 Dec; 18(6):5977-5985. PubMed ID: 31788072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of Mismatch Repair Deficiency Status and Microsatellite Instability in Relation to the Expression of Immune Checkpoint Proteins in Colorectal Cancer.
    Sharma A; Raphael V; Lyngdoh BS; Harris C; Jagtap VK
    Cureus; 2023 Aug; 15(8):e43571. PubMed ID: 37719521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor mutation burden and checkpoint immunotherapy markers in primary and metastatic synovial sarcoma.
    He M; Abro B; Kaushal M; Chen L; Chen T; Gondim M; Yan W; Neidich J; Dehner LP; Pfeifer JD
    Hum Pathol; 2020 Jun; 100():15-23. PubMed ID: 32387103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High expression of PD-1 ligands is associated with
    Boichard A; Tsigelny IF; Kurzrock R
    Oncoimmunology; 2017; 6(3):e1284719. PubMed ID: 28405512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful immune checkpoint blockade in a patient with advanced stage microsatellite-unstable biliary tract cancer.
    Czink E; Kloor M; Goeppert B; Fröhling S; Uhrig S; Weber TF; Meinel J; Sutter C; Weiss KH; Schirmacher P; Doeberitz MVK; Jäger D; Springfeld C
    Cold Spring Harb Mol Case Stud; 2017 Sep; 3(5):. PubMed ID: 28619747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. No Evidence of Microsatellite Instability and Loss of Mismatch-Repair-Protein Expression in Squamous Cell Carcinoma of the Penis.
    Stoehr R; Wendler O; Giedl J; Gaisa NT; Richter G; Campean V; Burger M; Wullich B; Bertz S; Hartmann A
    Pathobiology; 2019; 86(2-3):145-151. PubMed ID: 30650417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors.
    Sloan EA; Ring KL; Willis BC; Modesitt SC; Mills AM
    Am J Surg Pathol; 2017 Mar; 41(3):326-333. PubMed ID: 27984238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.